Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study
Background In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE). Methods Primary care practitioners collected information on patients presenting with acute respiratory infect...
Gespeichert in:
| Veröffentlicht in: | Influenza and other respiratory viruses 2023-01, Vol.17 (1), p.e13069-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 1 |
| container_start_page | e13069 |
| container_title | Influenza and other respiratory viruses |
| container_volume | 17 |
| creator | Kissling, Esther Pozo, Francisco Martínez‐Baz, Iván Buda, Silke Vilcu, Ana‐Maria Domegan, Lisa Mazagatos, Clara Dijkstra, Frederika Latorre‐Margalef, Neus Kurečić Filipović, Sanja Machado, Ausenda Lazar, Mihaela Casado, Itziar Dürrwald, Ralf Werf, Sylvie O'Donnell, Joan Linares Dopido, Juan Antonio Meijer, Adam Riess, Maximilian Višekruna Vučina, Vesna Rodrigues, Ana Paula Mihai, Maria Elena Castilla, Jesús Goerlitz, Luise Falchi, Alessandra Connell, Jeff Castrillejo, Daniel Hooiveld, Mariette Carnahan, Annasara Ilić, Maja Guiomar, Raquel Ivanciuc, Alina Maurel, Marine Omokanye, Ajibola Valenciano, Marta |
| description | Background
In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE).
Methods
Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions.
Results
Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43–89) and 81% (95% CI: 45–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12–42) and 25% (95% CI: −41 to 61), 33% (95% CI: 14–49), and 26% (95% CI: −22 to 55) among those aged 0–14, 15–64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: −6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2.
Discussion
Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I‐MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory‐confirmed influenza. |
| doi_str_mv | 10.1111/irv.13069 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9835407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2769857030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4819-21eb9071d0fdef69c2123d0f71b2ace322d9e065e1897eb7f8748e5741ff9a093</originalsourceid><addsrcrecordid>eNp1ks1u1DAQxyMEoqVw4AWQJS5wSDt2PhxzqLSqFrrSokoV9Go5ybjrKl_YcdBy6gNwQOIN-ySYZllBJXyZGfs3f4-tfxS9pHBMwzoxdjqmCeTiUXRIeQYxyzPxeJ-ncBA9c-4GIMuLLH0aHSQ5B8YFP4y-rzrdeOy-KTKpqjIdEtQaq9FM2KFzRF0r07mRmD23IM6X43ZAFzbJ0tt-wHfkEp1vRke07VsybpAwYPTu9mcIjKzubn98vLhaksGaVtktqZRF0oYGU2E3htyNvt4-j55o1Th8sYtH0ef3y09n5_H64sPqbLGOq7SgImYUSwGc1qBr1LmoGGVJKDgtmaowYawWCHmGtBAcS64LnhaY8ZRqLRSI5Cg6nXUHX7ZY34-gGrkbTvbKyH9POrOR1_0kRZFkKfAgEM8Cmwdt54u1HJQb0VsJKQguIJto4N_sLrT9F49ulK1xFTaN6rD3TjLOgTLgRRbQ1w_Qm97bLnxHoHJRZBwSCNTbmaps75xFvZ-CgvztCRk8Ie89EdhXf792T_4xQQBOZuCraXD7fyW5uryaJX8BiZ3DaQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2769857030</pqid></control><display><type>article</type><title>Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kissling, Esther ; Pozo, Francisco ; Martínez‐Baz, Iván ; Buda, Silke ; Vilcu, Ana‐Maria ; Domegan, Lisa ; Mazagatos, Clara ; Dijkstra, Frederika ; Latorre‐Margalef, Neus ; Kurečić Filipović, Sanja ; Machado, Ausenda ; Lazar, Mihaela ; Casado, Itziar ; Dürrwald, Ralf ; Werf, Sylvie ; O'Donnell, Joan ; Linares Dopido, Juan Antonio ; Meijer, Adam ; Riess, Maximilian ; Višekruna Vučina, Vesna ; Rodrigues, Ana Paula ; Mihai, Maria Elena ; Castilla, Jesús ; Goerlitz, Luise ; Falchi, Alessandra ; Connell, Jeff ; Castrillejo, Daniel ; Hooiveld, Mariette ; Carnahan, Annasara ; Ilić, Maja ; Guiomar, Raquel ; Ivanciuc, Alina ; Maurel, Marine ; Omokanye, Ajibola ; Valenciano, Marta</creator><creatorcontrib>Kissling, Esther ; Pozo, Francisco ; Martínez‐Baz, Iván ; Buda, Silke ; Vilcu, Ana‐Maria ; Domegan, Lisa ; Mazagatos, Clara ; Dijkstra, Frederika ; Latorre‐Margalef, Neus ; Kurečić Filipović, Sanja ; Machado, Ausenda ; Lazar, Mihaela ; Casado, Itziar ; Dürrwald, Ralf ; Werf, Sylvie ; O'Donnell, Joan ; Linares Dopido, Juan Antonio ; Meijer, Adam ; Riess, Maximilian ; Višekruna Vučina, Vesna ; Rodrigues, Ana Paula ; Mihai, Maria Elena ; Castilla, Jesús ; Goerlitz, Luise ; Falchi, Alessandra ; Connell, Jeff ; Castrillejo, Daniel ; Hooiveld, Mariette ; Carnahan, Annasara ; Ilić, Maja ; Guiomar, Raquel ; Ivanciuc, Alina ; Maurel, Marine ; Omokanye, Ajibola ; Valenciano, Marta ; I-MOVE study team ; I‐MOVE study team</creatorcontrib><description>Background
In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE).
Methods
Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions.
Results
Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43–89) and 81% (95% CI: 45–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12–42) and 25% (95% CI: −41 to 61), 33% (95% CI: 14–49), and 26% (95% CI: −22 to 55) among those aged 0–14, 15–64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: −6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2.
Discussion
Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I‐MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory‐confirmed influenza.</description><identifier>ISSN: 1750-2640</identifier><identifier>ISSN: 1750-2659</identifier><identifier>EISSN: 1750-2659</identifier><identifier>DOI: 10.1111/irv.13069</identifier><identifier>PMID: 36702797</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Antigens ; Case-Control Studies ; Child ; Child, Preschool ; Chronic conditions ; Chronic illnesses ; Disease transmission ; Effectiveness ; Europe ; Europe - epidemiology ; Female ; Health care ; Humans ; Immunization ; Infant ; Infant, Newborn ; Influenza ; Influenza A ; Influenza A Virus, H1N1 Subtype ; Influenza A Virus, H3N2 Subtype - genetics ; influenza vaccine ; Influenza Vaccines ; Influenza, Human - epidemiology ; Influenza, Human - prevention & control ; Life Sciences ; Male ; Middle Aged ; multicentre study ; Original ; Pandemics ; Primary care ; Primary Health Care ; Respiratory diseases ; Vaccination ; vaccine effectiveness ; Vaccine Efficacy ; Vaccines ; Viruses ; Young Adult</subject><ispartof>Influenza and other respiratory viruses, 2023-01, Vol.17 (1), p.e13069-n/a</ispartof><rights>2022 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.</rights><rights>2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4819-21eb9071d0fdef69c2123d0f71b2ace322d9e065e1897eb7f8748e5741ff9a093</citedby><cites>FETCH-LOGICAL-c4819-21eb9071d0fdef69c2123d0f71b2ace322d9e065e1897eb7f8748e5741ff9a093</cites><orcidid>0000-0002-2056-1062 ; 0000-0002-1849-1499 ; 0000-0002-6396-7265 ; 0000-0002-3432-0438 ; 0000-0002-6909-6923 ; 0000-0002-7483-6703 ; 0000-0001-7188-8404 ; 0000-0001-8074-7582</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835407/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835407/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36702797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://pasteur.hal.science/pasteur-04097905$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kissling, Esther</creatorcontrib><creatorcontrib>Pozo, Francisco</creatorcontrib><creatorcontrib>Martínez‐Baz, Iván</creatorcontrib><creatorcontrib>Buda, Silke</creatorcontrib><creatorcontrib>Vilcu, Ana‐Maria</creatorcontrib><creatorcontrib>Domegan, Lisa</creatorcontrib><creatorcontrib>Mazagatos, Clara</creatorcontrib><creatorcontrib>Dijkstra, Frederika</creatorcontrib><creatorcontrib>Latorre‐Margalef, Neus</creatorcontrib><creatorcontrib>Kurečić Filipović, Sanja</creatorcontrib><creatorcontrib>Machado, Ausenda</creatorcontrib><creatorcontrib>Lazar, Mihaela</creatorcontrib><creatorcontrib>Casado, Itziar</creatorcontrib><creatorcontrib>Dürrwald, Ralf</creatorcontrib><creatorcontrib>Werf, Sylvie</creatorcontrib><creatorcontrib>O'Donnell, Joan</creatorcontrib><creatorcontrib>Linares Dopido, Juan Antonio</creatorcontrib><creatorcontrib>Meijer, Adam</creatorcontrib><creatorcontrib>Riess, Maximilian</creatorcontrib><creatorcontrib>Višekruna Vučina, Vesna</creatorcontrib><creatorcontrib>Rodrigues, Ana Paula</creatorcontrib><creatorcontrib>Mihai, Maria Elena</creatorcontrib><creatorcontrib>Castilla, Jesús</creatorcontrib><creatorcontrib>Goerlitz, Luise</creatorcontrib><creatorcontrib>Falchi, Alessandra</creatorcontrib><creatorcontrib>Connell, Jeff</creatorcontrib><creatorcontrib>Castrillejo, Daniel</creatorcontrib><creatorcontrib>Hooiveld, Mariette</creatorcontrib><creatorcontrib>Carnahan, Annasara</creatorcontrib><creatorcontrib>Ilić, Maja</creatorcontrib><creatorcontrib>Guiomar, Raquel</creatorcontrib><creatorcontrib>Ivanciuc, Alina</creatorcontrib><creatorcontrib>Maurel, Marine</creatorcontrib><creatorcontrib>Omokanye, Ajibola</creatorcontrib><creatorcontrib>Valenciano, Marta</creatorcontrib><creatorcontrib>I-MOVE study team</creatorcontrib><creatorcontrib>I‐MOVE study team</creatorcontrib><title>Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study</title><title>Influenza and other respiratory viruses</title><addtitle>Influenza Other Respir Viruses</addtitle><description>Background
In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE).
Methods
Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions.
Results
Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43–89) and 81% (95% CI: 45–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12–42) and 25% (95% CI: −41 to 61), 33% (95% CI: 14–49), and 26% (95% CI: −22 to 55) among those aged 0–14, 15–64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: −6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2.
Discussion
Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I‐MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory‐confirmed influenza.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antigens</subject><subject>Case-Control Studies</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Chronic conditions</subject><subject>Chronic illnesses</subject><subject>Disease transmission</subject><subject>Effectiveness</subject><subject>Europe</subject><subject>Europe - epidemiology</subject><subject>Female</subject><subject>Health care</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Influenza</subject><subject>Influenza A</subject><subject>Influenza A Virus, H1N1 Subtype</subject><subject>Influenza A Virus, H3N2 Subtype - genetics</subject><subject>influenza vaccine</subject><subject>Influenza Vaccines</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - prevention & control</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multicentre study</subject><subject>Original</subject><subject>Pandemics</subject><subject>Primary care</subject><subject>Primary Health Care</subject><subject>Respiratory diseases</subject><subject>Vaccination</subject><subject>vaccine effectiveness</subject><subject>Vaccine Efficacy</subject><subject>Vaccines</subject><subject>Viruses</subject><subject>Young Adult</subject><issn>1750-2640</issn><issn>1750-2659</issn><issn>1750-2659</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1ks1u1DAQxyMEoqVw4AWQJS5wSDt2PhxzqLSqFrrSokoV9Go5ybjrKl_YcdBy6gNwQOIN-ySYZllBJXyZGfs3f4-tfxS9pHBMwzoxdjqmCeTiUXRIeQYxyzPxeJ-ncBA9c-4GIMuLLH0aHSQ5B8YFP4y-rzrdeOy-KTKpqjIdEtQaq9FM2KFzRF0r07mRmD23IM6X43ZAFzbJ0tt-wHfkEp1vRke07VsybpAwYPTu9mcIjKzubn98vLhaksGaVtktqZRF0oYGU2E3htyNvt4-j55o1Th8sYtH0ef3y09n5_H64sPqbLGOq7SgImYUSwGc1qBr1LmoGGVJKDgtmaowYawWCHmGtBAcS64LnhaY8ZRqLRSI5Cg6nXUHX7ZY34-gGrkbTvbKyH9POrOR1_0kRZFkKfAgEM8Cmwdt54u1HJQb0VsJKQguIJto4N_sLrT9F49ulK1xFTaN6rD3TjLOgTLgRRbQ1w_Qm97bLnxHoHJRZBwSCNTbmaps75xFvZ-CgvztCRk8Ie89EdhXf792T_4xQQBOZuCraXD7fyW5uryaJX8BiZ3DaQ</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Kissling, Esther</creator><creator>Pozo, Francisco</creator><creator>Martínez‐Baz, Iván</creator><creator>Buda, Silke</creator><creator>Vilcu, Ana‐Maria</creator><creator>Domegan, Lisa</creator><creator>Mazagatos, Clara</creator><creator>Dijkstra, Frederika</creator><creator>Latorre‐Margalef, Neus</creator><creator>Kurečić Filipović, Sanja</creator><creator>Machado, Ausenda</creator><creator>Lazar, Mihaela</creator><creator>Casado, Itziar</creator><creator>Dürrwald, Ralf</creator><creator>Werf, Sylvie</creator><creator>O'Donnell, Joan</creator><creator>Linares Dopido, Juan Antonio</creator><creator>Meijer, Adam</creator><creator>Riess, Maximilian</creator><creator>Višekruna Vučina, Vesna</creator><creator>Rodrigues, Ana Paula</creator><creator>Mihai, Maria Elena</creator><creator>Castilla, Jesús</creator><creator>Goerlitz, Luise</creator><creator>Falchi, Alessandra</creator><creator>Connell, Jeff</creator><creator>Castrillejo, Daniel</creator><creator>Hooiveld, Mariette</creator><creator>Carnahan, Annasara</creator><creator>Ilić, Maja</creator><creator>Guiomar, Raquel</creator><creator>Ivanciuc, Alina</creator><creator>Maurel, Marine</creator><creator>Omokanye, Ajibola</creator><creator>Valenciano, Marta</creator><general>John Wiley & Sons, Inc</general><general>Wiley Open Access</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2056-1062</orcidid><orcidid>https://orcid.org/0000-0002-1849-1499</orcidid><orcidid>https://orcid.org/0000-0002-6396-7265</orcidid><orcidid>https://orcid.org/0000-0002-3432-0438</orcidid><orcidid>https://orcid.org/0000-0002-6909-6923</orcidid><orcidid>https://orcid.org/0000-0002-7483-6703</orcidid><orcidid>https://orcid.org/0000-0001-7188-8404</orcidid><orcidid>https://orcid.org/0000-0001-8074-7582</orcidid></search><sort><creationdate>202301</creationdate><title>Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study</title><author>Kissling, Esther ; Pozo, Francisco ; Martínez‐Baz, Iván ; Buda, Silke ; Vilcu, Ana‐Maria ; Domegan, Lisa ; Mazagatos, Clara ; Dijkstra, Frederika ; Latorre‐Margalef, Neus ; Kurečić Filipović, Sanja ; Machado, Ausenda ; Lazar, Mihaela ; Casado, Itziar ; Dürrwald, Ralf ; Werf, Sylvie ; O'Donnell, Joan ; Linares Dopido, Juan Antonio ; Meijer, Adam ; Riess, Maximilian ; Višekruna Vučina, Vesna ; Rodrigues, Ana Paula ; Mihai, Maria Elena ; Castilla, Jesús ; Goerlitz, Luise ; Falchi, Alessandra ; Connell, Jeff ; Castrillejo, Daniel ; Hooiveld, Mariette ; Carnahan, Annasara ; Ilić, Maja ; Guiomar, Raquel ; Ivanciuc, Alina ; Maurel, Marine ; Omokanye, Ajibola ; Valenciano, Marta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4819-21eb9071d0fdef69c2123d0f71b2ace322d9e065e1897eb7f8748e5741ff9a093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antigens</topic><topic>Case-Control Studies</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Chronic conditions</topic><topic>Chronic illnesses</topic><topic>Disease transmission</topic><topic>Effectiveness</topic><topic>Europe</topic><topic>Europe - epidemiology</topic><topic>Female</topic><topic>Health care</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Influenza</topic><topic>Influenza A</topic><topic>Influenza A Virus, H1N1 Subtype</topic><topic>Influenza A Virus, H3N2 Subtype - genetics</topic><topic>influenza vaccine</topic><topic>Influenza Vaccines</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - prevention & control</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multicentre study</topic><topic>Original</topic><topic>Pandemics</topic><topic>Primary care</topic><topic>Primary Health Care</topic><topic>Respiratory diseases</topic><topic>Vaccination</topic><topic>vaccine effectiveness</topic><topic>Vaccine Efficacy</topic><topic>Vaccines</topic><topic>Viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kissling, Esther</creatorcontrib><creatorcontrib>Pozo, Francisco</creatorcontrib><creatorcontrib>Martínez‐Baz, Iván</creatorcontrib><creatorcontrib>Buda, Silke</creatorcontrib><creatorcontrib>Vilcu, Ana‐Maria</creatorcontrib><creatorcontrib>Domegan, Lisa</creatorcontrib><creatorcontrib>Mazagatos, Clara</creatorcontrib><creatorcontrib>Dijkstra, Frederika</creatorcontrib><creatorcontrib>Latorre‐Margalef, Neus</creatorcontrib><creatorcontrib>Kurečić Filipović, Sanja</creatorcontrib><creatorcontrib>Machado, Ausenda</creatorcontrib><creatorcontrib>Lazar, Mihaela</creatorcontrib><creatorcontrib>Casado, Itziar</creatorcontrib><creatorcontrib>Dürrwald, Ralf</creatorcontrib><creatorcontrib>Werf, Sylvie</creatorcontrib><creatorcontrib>O'Donnell, Joan</creatorcontrib><creatorcontrib>Linares Dopido, Juan Antonio</creatorcontrib><creatorcontrib>Meijer, Adam</creatorcontrib><creatorcontrib>Riess, Maximilian</creatorcontrib><creatorcontrib>Višekruna Vučina, Vesna</creatorcontrib><creatorcontrib>Rodrigues, Ana Paula</creatorcontrib><creatorcontrib>Mihai, Maria Elena</creatorcontrib><creatorcontrib>Castilla, Jesús</creatorcontrib><creatorcontrib>Goerlitz, Luise</creatorcontrib><creatorcontrib>Falchi, Alessandra</creatorcontrib><creatorcontrib>Connell, Jeff</creatorcontrib><creatorcontrib>Castrillejo, Daniel</creatorcontrib><creatorcontrib>Hooiveld, Mariette</creatorcontrib><creatorcontrib>Carnahan, Annasara</creatorcontrib><creatorcontrib>Ilić, Maja</creatorcontrib><creatorcontrib>Guiomar, Raquel</creatorcontrib><creatorcontrib>Ivanciuc, Alina</creatorcontrib><creatorcontrib>Maurel, Marine</creatorcontrib><creatorcontrib>Omokanye, Ajibola</creatorcontrib><creatorcontrib>Valenciano, Marta</creatorcontrib><creatorcontrib>I-MOVE study team</creatorcontrib><creatorcontrib>I‐MOVE study team</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Influenza and other respiratory viruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kissling, Esther</au><au>Pozo, Francisco</au><au>Martínez‐Baz, Iván</au><au>Buda, Silke</au><au>Vilcu, Ana‐Maria</au><au>Domegan, Lisa</au><au>Mazagatos, Clara</au><au>Dijkstra, Frederika</au><au>Latorre‐Margalef, Neus</au><au>Kurečić Filipović, Sanja</au><au>Machado, Ausenda</au><au>Lazar, Mihaela</au><au>Casado, Itziar</au><au>Dürrwald, Ralf</au><au>Werf, Sylvie</au><au>O'Donnell, Joan</au><au>Linares Dopido, Juan Antonio</au><au>Meijer, Adam</au><au>Riess, Maximilian</au><au>Višekruna Vučina, Vesna</au><au>Rodrigues, Ana Paula</au><au>Mihai, Maria Elena</au><au>Castilla, Jesús</au><au>Goerlitz, Luise</au><au>Falchi, Alessandra</au><au>Connell, Jeff</au><au>Castrillejo, Daniel</au><au>Hooiveld, Mariette</au><au>Carnahan, Annasara</au><au>Ilić, Maja</au><au>Guiomar, Raquel</au><au>Ivanciuc, Alina</au><au>Maurel, Marine</au><au>Omokanye, Ajibola</au><au>Valenciano, Marta</au><aucorp>I-MOVE study team</aucorp><aucorp>I‐MOVE study team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study</atitle><jtitle>Influenza and other respiratory viruses</jtitle><addtitle>Influenza Other Respir Viruses</addtitle><date>2023-01</date><risdate>2023</risdate><volume>17</volume><issue>1</issue><spage>e13069</spage><epage>n/a</epage><pages>e13069-n/a</pages><issn>1750-2640</issn><issn>1750-2659</issn><eissn>1750-2659</eissn><abstract>Background
In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE).
Methods
Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions.
Results
Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43–89) and 81% (95% CI: 45–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12–42) and 25% (95% CI: −41 to 61), 33% (95% CI: 14–49), and 26% (95% CI: −22 to 55) among those aged 0–14, 15–64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: −6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2.
Discussion
Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I‐MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory‐confirmed influenza.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>36702797</pmid><doi>10.1111/irv.13069</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2056-1062</orcidid><orcidid>https://orcid.org/0000-0002-1849-1499</orcidid><orcidid>https://orcid.org/0000-0002-6396-7265</orcidid><orcidid>https://orcid.org/0000-0002-3432-0438</orcidid><orcidid>https://orcid.org/0000-0002-6909-6923</orcidid><orcidid>https://orcid.org/0000-0002-7483-6703</orcidid><orcidid>https://orcid.org/0000-0001-7188-8404</orcidid><orcidid>https://orcid.org/0000-0001-8074-7582</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-2640 |
| ispartof | Influenza and other respiratory viruses, 2023-01, Vol.17 (1), p.e13069-n/a |
| issn | 1750-2640 1750-2659 1750-2659 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9835407 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; DOAJ Directory of Open Access Journals; Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adolescent Adult Aged Antigens Case-Control Studies Child Child, Preschool Chronic conditions Chronic illnesses Disease transmission Effectiveness Europe Europe - epidemiology Female Health care Humans Immunization Infant Infant, Newborn Influenza Influenza A Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype - genetics influenza vaccine Influenza Vaccines Influenza, Human - epidemiology Influenza, Human - prevention & control Life Sciences Male Middle Aged multicentre study Original Pandemics Primary care Primary Health Care Respiratory diseases Vaccination vaccine effectiveness Vaccine Efficacy Vaccines Viruses Young Adult |
| title | Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A46%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influenza%20vaccine%20effectiveness%20against%20influenza%20A%20subtypes%20in%20Europe:%20Results%20from%20the%202021%E2%80%932022%20I%E2%80%90MOVE%20primary%20care%20multicentre%20study&rft.jtitle=Influenza%20and%20other%20respiratory%20viruses&rft.au=Kissling,%20Esther&rft.aucorp=I-MOVE%20study%20team&rft.date=2023-01&rft.volume=17&rft.issue=1&rft.spage=e13069&rft.epage=n/a&rft.pages=e13069-n/a&rft.issn=1750-2640&rft.eissn=1750-2659&rft_id=info:doi/10.1111/irv.13069&rft_dat=%3Cproquest_pubme%3E2769857030%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2769857030&rft_id=info:pmid/36702797&rfr_iscdi=true |